Dr Fragkou holds a PhD in Electrochemical Biosensors from Cranfield University. She has prior to AegirBio worked in leading roles and has a proven background and expertise in the development of in-vitro diagnostic medical devices from its inception to successful launch.
Dr. Fragkou’s leadership as COO will strengthen the company’s position as an industry leader, driving innovation, and ultimately benefiting patients and healthcare providers alike. Dr. Fragkou will replace Dr Nils Paulsson.
CEO Marco Witteveen states; “As the current UK Operations Director, Dr. Fragkou has demonstrated leadership, strategic acumen, and an unwavering commitment to advancing the company’s objectives. In her new capacity, she will play an important role in driving AegirBio’s innovative platform development and expediting time-to-market.”
EN 
ES